Results from the global phase III Harmoni trial presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) showed a statistically significant increase in progression-free survival after treatment with ivonescimab plus chemotherapy compared to chemotherapy alone, but failed to show a statistically significant benefit in overall survival (OS).
IMU Biosciences Ltd. is working to transform society’s understanding of the immune system. The company’s platform maps the immune system at molecular, cellular and system levels, to unlock new insights into immune-related health and diseases, paving the way for clinical applications that could improve patient outcomes.
Investigators at the University of Texas have synthesized new mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) and Bruton tyrosine kinase (BTK) dual-target inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
A Juno Therapeutics Inc. patent describes pyrazole-based DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.
Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), an enzyme involved in one-carbon metabolism, is significantly overexpressed in cancer cells but shows limited expression in normal tissues, making it a promising target for cancer therapy.
Lila Biologics Inc. has entered into a global licensing and multitarget research collaboration with Eli Lilly & Co. focused on the discovery, development and commercialization of novel radioligand therapies for imaging and treatment of solid tumors.
IMU Biosciences Ltd. is working to transform society’s understanding of the immune system. The company’s platform maps the immune system at molecular, cellular and system levels, to unlock new insights into immune-related health and diseases, paving the way for clinical applications that could improve patient outcomes.
Detailed data are expected later, but partners Biontech SE and Duality Biologics Co. Ltd. are celebrating a phase III interim analysis readout demonstrating that HER2-targeting antibody-drug conjugate (ADC) trastuzumab pamirtecan hit the primary endpoint of progression-free survival in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and a taxane-based chemotherapy.
RSS
